Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Allergic Reactions02:06

Allergic Reactions

Overview
Antigens Involved in Adaptive Immunity01:26

Antigens Involved in Adaptive Immunity

An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and reactivity.
Allergic Reactions: Anaphylaxis01:30

Allergic Reactions: Anaphylaxis

Anaphylaxis is a severe, life-threatening hypersensitivity reaction mediated by Immunoglobulin E (IgE) antibodies. When IgE binds to allergens, it triggers the release of mediators– histamine, leukotrienes, and prostaglandins from mast cells and basophils. These mediators cause vasodilation, edema, and inflammation, leading to various symptoms.The primary allergens causing anaphylaxis include food items (e.g., peanuts, shellfish), drugs (e.g., penicillin, asparaginase, corticotropin, heparin),...
Cross-reactivity00:42

Cross-reactivity

Overview
Allergic Drug Reactions01:27

Allergic Drug Reactions

Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing numerous...
Recombinant DNA01:09

Recombinant DNA

Overview

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Trained immunity and tolerance in innate lymphoid cells, monocytes, and dendritic cells during allergen-specific immunotherapy.

The Journal of allergy and clinical immunology·2020
Same author

Perspectives in allergen immunotherapy: 2019 and beyond.

Allergy·2019
Same author

WHO/IUIS Allergen Nomenclature: Providing a common language.

Molecular immunology·2018
Same author

Sialylation of IgG antibodies inhibits IgG-mediated allergic reactions.

The Journal of allergy and clinical immunology·2017
Same author

Allergen specific immunotherapy has no influence on standard chemistry and hematology laboratory parameters in clinical studies.

Clinical and translational allergy·2014
Same author

Recombinant allergens for SIT of mite allergy.

Arbeiten aus dem Paul-Ehrlich-Institut (Bundesinstitut fur Impfstoffe und biomedizinische Arzneimittel) Langen/Hessen·2014

Related Experiment Video

Updated: Jun 3, 2026

Humanized Mediator Release Assay as a Read-Out for Allergen Potency
10:22

Humanized Mediator Release Assay as a Read-Out for Allergen Potency

Published on: June 29, 2021

Recombinant allergens for specific immunotherapy.

Oliver Cromwell1, Dietrich Häfner, Andreas Nandy

  • 1Research and Development Division, Allergopharma Joachim Ganzer KG, Reinbek, Germany. oliver.cromwell@allergopharma.de

The Journal of Allergy and Clinical Immunology
|March 8, 2011
PubMed
Summary

Recombinant DNA technology enables the production of precise allergens for detailed allergy diagnosis and immunotherapy. Genetically engineered variants offer safer, more effective treatments, with new products anticipated within five years.

More Related Videos

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

Intralymphatic Immunotherapy and Vaccination in Mice
07:33

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

Related Experiment Videos

Last Updated: Jun 3, 2026

Humanized Mediator Release Assay as a Read-Out for Allergen Potency
10:22

Humanized Mediator Release Assay as a Read-Out for Allergen Potency

Published on: June 29, 2021

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

Intralymphatic Immunotherapy and Vaccination in Mice
07:33

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

Area of Science:

  • Biotechnology
  • Immunology
  • Allergy Research

Background:

  • Recombinant DNA technology allows for the production of highly consistent and well-defined allergen proteins.
  • This technology facilitates the creation of both natural allergen equivalents and modified variants with reduced allergenic potential.

Purpose of the Study:

  • To explore the application of recombinant allergens in advanced allergy diagnostics.
  • To evaluate the efficacy and safety of recombinant allergens in immunotherapy, including hypoallergenic variants.
  • To project the timeline for the market introduction of novel recombinant allergen-based therapies.

Main Methods:

  • Cloning and expression of several hundred allergens as recombinant proteins.
  • Development of genetically engineered hypoallergenic variants with reduced IgE-binding activity.
  • Clinical trials for subcutaneous and sublingual immunotherapy using recombinant allergens and their variants.

Main Results:

  • Recombinant allergens enable highly detailed patient sensitization profiling.
  • Clinical studies demonstrate the effectiveness of recombinant grass and birch pollen preparations in immunotherapy.
  • Hypoallergenic variants are progressing in clinical trials for enhanced safety and tolerability.

Conclusions:

  • Recombinant allergens represent a significant advancement in allergy diagnosis and treatment.
  • The development of hypoallergenic recombinant allergens holds promise for safer and more effective immunotherapies.
  • While personalized immunotherapy remains a future goal, initial recombinant allergen products are nearing market availability.